KI2011

KI2011 is a novel, potent small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3), specifically designed as an oxazole amine derivative. It demonstrates high inhibitory activity against wild-type FLT3, the FLT3-D835Y point mutation, and the FLT3-internal tandem duplication (ITD) mutation, which are common drivers of poor prognosis in acute myeloid leukemia (AML). Developed by researchers at the Korea Institute of Radiological & Medical Sciences, KI2011 works by blocking FLT3 auto-phosphorylation and its downstream signaling pathways, leading to selective inhibition of cell proliferation and induction of apoptosis in FLT3-mutated AML cells. Additionally, it has been shown to enhance the radiosensitivity of leukemia cells, suggesting potential for combination therapy.